"Pregnancy and neuroendocrine neoplasms: what we know and do not know?"

Alexandraki, Krystallenia I.

DOI: https://doi.org/10.1007/s40336-024-00660-1

2024-10-17

Clinical and Translational Imaging

Abstract:Neuroendocrine neoplasms (NEN) are rather rare tumors, but their incidence is constantly rising in recent years. Although NEN guidelines summarize the recommendations for the diagnosis and treatment of this heterogeneous group of neoplasms, their handling during pregnancy is not well defined. NEN are rare entities during pregnancy, and their prevalence increases because of an earlier diagnosis also in genetic syndromes. Their diagnosis in gestation can be challenging due to their symptoms that can easily be confused with symptoms of pregnancy. The radiation exposure poses further diagnostic problems as several modalities cannot be applied during pregnancy. Surgery remains the mainstay of NEN treatment, but anesthesia in combination with secretory syndromes such as carcinoid syndrome requires specific approaches. Pharmacological treatments are not well established in pregnant patients with NEN and are so far only applied in specific settings, with somatostatin analogues being mostly tested to date. Collaborative efforts across specialties such as endocrinology, obstetrics gynecology, surgery, oncology and anesthesia are essential to devise effective treatment strategies. Critical considerations include the selection of appropriate medical therapies, timing of surgical interventions, decisions regarding delivery methods and timing, and evaluation of anesthesia protocols. The present paper aims to concisely summarize the complexity of diagnosis and treatment of NEN during pregnancy with focus on a variety of real-life scenarios and on the many unmet needs to be carefully considered in the clinical practice.

radiology, nuclear medicine & medical imaging